Biomodulatory metronomic therapy in stage IV melanoma is well‐tolerated and may induce prolonged progression‐free survival, a phase I trial

Detalles Bibliográficos
Autores principales: Hart, C., Vogelhuber, M., Hafner, C., Landthaler, M., Berneburg, M., Haferkamp, S., Herr, W., Reichle, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108438/
https://www.ncbi.nlm.nih.gov/pubmed/26417987
http://dx.doi.org/10.1111/jdv.13391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108438/
https://www.ncbi.nlm.nih.gov/pubmed/26417987
http://dx.doi.org/10.1111/jdv.13391

Ejemplares similares